search
Back to results

MDPK67b in Patients With Prostate Cancer

Primary Purpose

Prostate Cancer

Status
Recruiting
Phase
Phase 1
Locations
Switzerland
Study Type
Interventional
Intervention
MDPK67b
Sponsored by
Med Discovery SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prostate Cancer focused on measuring prostate cancer, radical prostatectomy, Gleason score 7 or higher

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Subject screening criteria

  1. Patients aged 18 years or older.
  2. Patients who have untreated suspected PCa or PCa under active surveillance (AS) with progression/upgrading.
  3. Patients who signed a written screening phase ICF.

Subject non-screening criteria

  1. Patients who have an uncontrolled disease that would unduly increase the risk of toxicity or limit compliance with study requirements in the opinion of the Investigator; including but not limited to: ongoing or active symptomatic infection, uncontrolled diabetes mellitus, diseases of the coagulation system, unstable or uncompensated cardiac, hepatic, renal, respiratory, or psychiatric disease.
  2. Patients who required a significant change in their concomitant medications during the week prior to screening visit, or who will likely need to have a change in their concomitant medications during the study. This includes any medication other than those required for PCa diagnosis or for RPE.
  3. Patients who have received prior radiotherapy to the prostate.
  4. Patients who have had prior exposure to MDPK67b.
  5. Patients who have participated in another clinical trial within 3 months prior to screening visit, except if in the opinion of the investigator the type of trial does not interfere in any way with the present trial (eg. non-interventional observational trial). In case of doubt, the sponsor's prior approval must be obtained and the decision to include such a patient will be documented in detail.

Non-screening criteria are exclusion criteria for the screening phase.

For the patients not participating in the screening phase (ie patients with previously established PCa diagnosis), all the criteria above shall be checked prior to enrolment in the treatment phase. However, these patients do not have to sign a screening ICF (screening criterion n°3 is not applicable), and for non-screening criterion n°5, the 3-month wash-out period is prior to the inclusion visit in the treatment phase.

Subject inclusion criteria

  1. Patients who still meet all the eligibility criteria checked at screening visit.
  2. Patients who have untreated PCa with a Gleason score of 7 (preferably) or higher, with local disease or with metastatic disease (if metastatic, no visceral metastases, no more than five bone or lymph node metastases), and are scheduled to undergo RPE about 3 weeks later.
  3. Patients with an expected minimal survival time of 12 months.
  4. Patients who have an acceptable organ and marrow function as assessed at the inclusion visit and defined as follows:

    1. Absolute neutrophil count ≥ 1.5 × 109/L.
    2. Platelets ≥ 100 × 109/L.
    3. Hemoglobin ≥ 9 g/dL.
    4. Total bilirubin ≤ 1.5 × ULN, unless the patient has known Gilbert's syndrome.
    5. Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN in presence of liver metastasis.
    6. Serum creatinine ≤ 2.0 × ULN, or GFR ≥ 30 mL/min by Cockcroft-Gault.
    7. INR <1.5, aPTT < 60 s
  5. Patients with an ECOG performance status ≤ 1.
  6. Patients who agree to refrain to donate sperm for the duration of the study.
  7. Patients who signed a written treatment phase ICF.

Sites / Locations

  • Klinik für Urologie, UniversitätSpital Zürich (USZ)Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Dose

Arm Description

Five patients will be included into the 24 mg dose level. In case of dose limiting toxicity (DLT) in at least one patient, 5 additional patients will be enrolled in the 24 mg dose level. If the treatment is well tolerated, i.e. no DLT is encountered, the dose of MDPK67b is escalated to 48 mg on a second cohort of 5 patients. In case of DLT in at least one patient at the 48 mg dose level, the 24 mg dose level of MDPK67b is expanded from 5 to 10 patients, or declared the maximum tolerated dose (MTD) if already expanded to 10 patients.

Outcomes

Primary Outcome Measures

Tolerability and Safety
Number of subjects with changes in blood pressure
Tolerability and Safety
Number of subjects with changes in blood pressure
Tolerability and Safety
Number of subjects with changes in blood pressure
Tolerability and Safety
Number of subjects with changes in blood pressure
Tolerability and Safety
Body temperature
Tolerability and Safety
Number of subjects with changes in body temperature
Tolerability and Safety
Number of subjects with changes in body temperature
Tolerability and Safety
Number of subjects with changes in body temperature
Tolerability and Safety
Number of subjects with changes in respiration rate
Tolerability and Safety
Number of subjects with changes in respiration rate
Tolerability and Safety
Number of subjects with changes in respiration rate
Tolerability and Safety
Number of subjects with changes in respiration rate
Tolerability and Safety
Number of subjects with changes in weight
Tolerability and Safety
Number of subjects with changes in weight
Tolerability and Safety
Number of subjects with changes in weight
Tolerability and Safety
Number of subjects with changes in weight
Tolerability and Safety
Number of subjects with changes in QTc on ECG
Tolerability and Safety
Number of subjects with changes in QTc on ECG
Tolerability and Safety
Number of subjects with changes in QTc on ECG
Tolerability and Safety
Number of subjects with changes in QTc on ECG
Tolerability and Safety
Number of subjects with changes in heart rate on ECG
Tolerability and Safety
Number of subjects with changes in heart rate on ECG
Tolerability and Safety
Number of subjects with changes in heart rate on ECG
Tolerability and Safety
Number of subjects with changes in heart rate on ECG
Tolerability and Safety
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
Tolerability and Safety
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
Tolerability and Safety
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
Tolerability and Safety
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
Tolerability and Safety
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
Tolerability and Safety
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
Tolerability and Safety
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
Tolerability and Safety
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
Tolerability and Safety
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
Tolerability and Safety
Number of subjects with changes in physical examination
Tolerability and Safety
Number of subjects with changes in physical examination
Tolerability and Safety
Number of subjects with changes in physical examination
Tolerability and Safety
Number of subjects with changes in physical examination
Tolerability and Safety
Adverse events
Tolerability and Safety
Adverse events
Tolerability and Safety
Adverse events
Tolerability and Safety
Adverse events
Tolerability and Safety
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
Tolerability and Safety
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
Tolerability and Safety
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)

Secondary Outcome Measures

Histo-pathological and molecular changes in prostate tumor tissue samples
Androgen receptor expression
Histo-pathological and molecular changes in prostate tumor tissue samples
Androgen receptor expression
Histo-pathological and molecular changes in prostate tumor tissue samples
Extent of proliferation using Ki67
Histo-pathological and molecular changes in prostate tumor tissue samples
Extent of proliferation using Ki67
Histo-pathological and molecular changes in prostate tumor tissue samples
Extent of inflammation using leukocyte markers
Histo-pathological and molecular changes in prostate tumor tissue samples
Extent of inflammation using leukocyte markers
Histo-pathological and molecular changes in prostate tumor tissue samples
Expression of KLK2, KLK4, and KLK14 using immunohistochemistry
Histo-pathological and molecular changes in prostate tumor tissue samples
Expression of KLK2, KLK4, and KLK14 using immunohistochemistry
Histo-pathological and molecular changes in prostate tumor tissue samples
Treatment induced change in RNA transcriptome assessed by RNA sequencing
Histo-pathological and molecular changes in prostate tumor tissue samples
Treatment induced change in RNA transcriptome assessed by RNA sequencing

Full Information

First Posted
July 7, 2022
Last Updated
October 11, 2022
Sponsor
Med Discovery SA
Collaborators
Camara and Partners Sàrl, Soladis
search

1. Study Identification

Unique Protocol Identification Number
NCT05580107
Brief Title
MDPK67b in Patients With Prostate Cancer
Official Title
Open-label Phase Ib Study of Preoperative Treatment With the KLK Inhibitor MDPK67b in Patients With Untreated Prostate Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 9, 2021 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Med Discovery SA
Collaborators
Camara and Partners Sàrl, Soladis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Administration of MDPK67b to assess its Tolerability and Safety profile in prostate cancer patients, and to assess histo-pathological and molecular changes in prostate tumor tissue samples.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
prostate cancer, radical prostatectomy, Gleason score 7 or higher

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Dose finding (24 and 48 mg) based on dose limiting toxicity (DLT)
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose
Arm Type
Experimental
Arm Description
Five patients will be included into the 24 mg dose level. In case of dose limiting toxicity (DLT) in at least one patient, 5 additional patients will be enrolled in the 24 mg dose level. If the treatment is well tolerated, i.e. no DLT is encountered, the dose of MDPK67b is escalated to 48 mg on a second cohort of 5 patients. In case of DLT in at least one patient at the 48 mg dose level, the 24 mg dose level of MDPK67b is expanded from 5 to 10 patients, or declared the maximum tolerated dose (MTD) if already expanded to 10 patients.
Intervention Type
Drug
Intervention Name(s)
MDPK67b
Intervention Description
24 mg or 48 mg
Primary Outcome Measure Information:
Title
Tolerability and Safety
Description
Number of subjects with changes in blood pressure
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in blood pressure
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in blood pressure
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in blood pressure
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Body temperature
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in body temperature
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in body temperature
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in body temperature
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in respiration rate
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in respiration rate
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in respiration rate
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in respiration rate
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in weight
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in weight
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in weight
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in weight
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in QTc on ECG
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in QTc on ECG
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in QTc on ECG
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in QTc on ECG
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in heart rate on ECG
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in heart rate on ECG
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in heart rate on ECG
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in heart rate on ECG
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in hematology safety parameters: haemoglobin, haematocrit, RBC, MCH, MCV, WBC differential count (absolute and relative count), platelet count, INR, aPTT, Thrombin time and fibrinogen
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in blood chemistry safety parameters: fasting glucose, total protein, creatinine, urea, sodium, potassium, calcium, uric acid, AST, ALT, CPK, AlkP, LDH, total bilirubin, PSA
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in urine safety parameters: pH, ketones, protein, glucose, blood, leukocytes, urobilinogen, bilirubin
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Number of subjects with changes in physical examination
Time Frame
Day 1
Title
Tolerability and Safety
Description
Number of subjects with changes in physical examination
Time Frame
Day 8
Title
Tolerability and Safety
Description
Number of subjects with changes in physical examination
Time Frame
Day 15
Title
Tolerability and Safety
Description
Number of subjects with changes in physical examination
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Adverse events
Time Frame
Day 1
Title
Tolerability and Safety
Description
Adverse events
Time Frame
Day 8
Title
Tolerability and Safety
Description
Adverse events
Time Frame
Day 15
Title
Tolerability and Safety
Description
Adverse events
Time Frame
Day 20-25
Title
Tolerability and Safety
Description
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
Time Frame
Day 1
Title
Tolerability and Safety
Description
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
Time Frame
Day 8
Title
Tolerability and Safety
Description
Local tolerance using the 5-point Draize scale (0: no irritation to 5: Frank vein thrombosis in addition to grade 4 signs and symptoms)
Time Frame
Day 15
Secondary Outcome Measure Information:
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Androgen receptor expression
Time Frame
Screening (Diagnostic biopsy)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Androgen receptor expression
Time Frame
Day 16/17 (Radical prostatectomy sample)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Extent of proliferation using Ki67
Time Frame
Screening (Diagnostic biopsy)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Extent of proliferation using Ki67
Time Frame
Day 16/17 (Radical prostatectomy sample)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Extent of inflammation using leukocyte markers
Time Frame
Screening (Diagnostic biopsy)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Extent of inflammation using leukocyte markers
Time Frame
Day 16/17 (Radical prostatectomy sample)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Expression of KLK2, KLK4, and KLK14 using immunohistochemistry
Time Frame
Screening (Diagnostic biopsy)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Expression of KLK2, KLK4, and KLK14 using immunohistochemistry
Time Frame
Day 16/17 (Radical prostatectomy sample)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Treatment induced change in RNA transcriptome assessed by RNA sequencing
Time Frame
Screening (Diagnostic biopsy)
Title
Histo-pathological and molecular changes in prostate tumor tissue samples
Description
Treatment induced change in RNA transcriptome assessed by RNA sequencing
Time Frame
Day 16/17 (Radical prostatectomy sample)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Subject screening criteria Patients aged 18 years or older. Patients who have untreated suspected PCa or PCa under active surveillance (AS) with progression/upgrading. Patients who signed a written screening phase ICF. Subject non-screening criteria Patients who have an uncontrolled disease that would unduly increase the risk of toxicity or limit compliance with study requirements in the opinion of the Investigator; including but not limited to: ongoing or active symptomatic infection, uncontrolled diabetes mellitus, diseases of the coagulation system, unstable or uncompensated cardiac, hepatic, renal, respiratory, or psychiatric disease. Patients who required a significant change in their concomitant medications during the week prior to screening visit, or who will likely need to have a change in their concomitant medications during the study. This includes any medication other than those required for PCa diagnosis or for RPE. Patients who have received prior radiotherapy to the prostate. Patients who have had prior exposure to MDPK67b. Patients who have participated in another clinical trial within 3 months prior to screening visit, except if in the opinion of the investigator the type of trial does not interfere in any way with the present trial (eg. non-interventional observational trial). In case of doubt, the sponsor's prior approval must be obtained and the decision to include such a patient will be documented in detail. Non-screening criteria are exclusion criteria for the screening phase. For the patients not participating in the screening phase (ie patients with previously established PCa diagnosis), all the criteria above shall be checked prior to enrolment in the treatment phase. However, these patients do not have to sign a screening ICF (screening criterion n°3 is not applicable), and for non-screening criterion n°5, the 3-month wash-out period is prior to the inclusion visit in the treatment phase. Subject inclusion criteria Patients who still meet all the eligibility criteria checked at screening visit. Patients who have untreated PCa with a Gleason score of 7 (preferably) or higher, with local disease or with metastatic disease (if metastatic, no visceral metastases, no more than five bone or lymph node metastases), and are scheduled to undergo RPE about 3 weeks later. Patients with an expected minimal survival time of 12 months. Patients who have an acceptable organ and marrow function as assessed at the inclusion visit and defined as follows: Absolute neutrophil count ≥ 1.5 × 109/L. Platelets ≥ 100 × 109/L. Hemoglobin ≥ 9 g/dL. Total bilirubin ≤ 1.5 × ULN, unless the patient has known Gilbert's syndrome. Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN in presence of liver metastasis. Serum creatinine ≤ 2.0 × ULN, or GFR ≥ 30 mL/min by Cockcroft-Gault. INR <1.5, aPTT < 60 s Patients with an ECOG performance status ≤ 1. Patients who agree to refrain to donate sperm for the duration of the study. Patients who signed a written treatment phase ICF.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christoph Kündig
Phone
+41 21 566 14 11
Email
christoph.kundig@med-discovery.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Eberli, Prof.
Organizational Affiliation
Klinik für Urologie, UniversitätSpital Zürich (USZ)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinik für Urologie, UniversitätSpital Zürich (USZ)
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Eberli, Prof.
Phone
+41 44 255 9619
Email
daniel.eberli@usz.ch

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

MDPK67b in Patients With Prostate Cancer

We'll reach out to this number within 24 hrs